Skip to main content

Table 3 Incidence of biomarkers in grade III gliomas in other studies

From: Incidence of biomarkers in high-grade gliomas and their impact on survival in a diverse SouthEast Asian cohort - a population-based study

Study

Year

Country

Number of patients tested

Incidence of Positive Biomarkers (%)

MGMT promoter methylation

1p19q co-deletion

IDH1 mutation

ATRX loss

Lassman et al. [28]

2011

USA

631

 

48

  

Boots-Sprenger et al. [24]

2013

Netherlands

51 (MGMT)

45

   

53 (1p19q)

 

51

  

115 (IDH1)

  

75

 

Wiestler et al. [29]

2013

Germany

133

   

33

Ogura et al. [20]

2015

Japan

101

36

 

35

 

Cai et al. [30]

2016

China

104

  

54

40

Ebrahimi et al. [31]

2016

Germany

245 (IDH1/2)

  

60a

 

239 (ATRX)

   

34

Polivka et al. [32]

2016

Czech Republic

23

 

52

  

Rajmohan et al. [21]

2016

India

91

81

53

84

30

Kramář et al. [33]

2016

Czech Republic

17

  

71a

 
  1. aIncludes IDH2 mutations. MGMT O6-methylguanine-DNA-transferase; IDH1 isocitrate dehydrogenase 1; ATRX alpha-thalassemia/mental retardation syndrome X-linked